EMA Withdrawn: Zalviso (sufentanil) — FGK Representative Service GmbH

View source ↗

Summary

Zalviso (sufentanil) has been withdrawn from the European market per EMA decision in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Postoperative Pain

Drugs mentioned

• Zalviso (sufentanil)

Snippet

Status: Withdrawn. Therapeutic area: Pain, Postoperative. MAH: FGK Representative Service GmbH. Decision date: 05/08/2022